COSMO Pharmaceuticals SA (0RGI) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.002x

Based on the latest financial reports, COSMO Pharmaceuticals SA (0RGI) has a cash flow conversion efficiency ratio of 0.002x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (£900.00K ≈ $1.21 Million USD) by net assets (£466.98 Million ≈ $627.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See COSMO Pharmaceuticals SA (0RGI) balance sheet quality index to measure how much of total assets are equity-financed.

COSMO Pharmaceuticals SA - Cash Flow Conversion Efficiency Trend (2004–2024)

This chart illustrates how COSMO Pharmaceuticals SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check COSMO Pharmaceuticals SA cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

COSMO Pharmaceuticals SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of COSMO Pharmaceuticals SA ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
North China Pharmaceutical Co Ltd
SHG:600812
0.025x
WEIBO CORP. A
F:2WB
N/A
Yapp Automotive Systems Co Ltd
SHG:603013
0.242x
Palfinger AG
VI:PAL
0.004x
Csg Smart Science&Technology Co Ltd
SHE:300222
0.084x
Three's Company Media Group Co Ltd
SHG:605168
-0.021x
Flow Traders BV
AS:FLOW
-1.463x
Faraday Copper Corp.
TO:FDY
0.012x

Annual Cash Flow Conversion Efficiency for COSMO Pharmaceuticals SA (2004–2024)

The table below shows the annual cash flow conversion efficiency of COSMO Pharmaceuticals SA from 2004 to 2024. For the full company profile with market capitalisation and key ratios, see market value of COSMO Pharmaceuticals SA.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 £505.09 Million
≈ $678.29 Million
£162.41 Million
≈ $218.10 Million
0.322x +507.52%
2023-12-31 £429.04 Million
≈ $576.16 Million
£22.71 Million
≈ $30.49 Million
0.053x -25.38%
2022-12-31 £463.79 Million
≈ $622.83 Million
£32.89 Million
≈ $44.17 Million
0.071x +188.34%
2021-12-31 £512.68 Million
≈ $688.48 Million
£12.61 Million
≈ $16.94 Million
0.025x -24.20%
2020-12-31 £400.12 Million
≈ $537.33 Million
£12.98 Million
≈ $17.44 Million
0.032x +167.80%
2019-12-31 £393.73 Million
≈ $528.75 Million
£-18.85 Million
≈ $-25.31 Million
-0.048x -109.50%
2018-12-31 £444.85 Million
≈ $597.40 Million
£-10.16 Million
≈ $-13.65 Million
-0.023x -7.32%
2017-12-31 £470.12 Million
≈ $631.32 Million
£-10.01 Million
≈ $-13.44 Million
-0.021x -133.50%
2016-12-31 £415.56 Million
≈ $558.06 Million
£26.41 Million
≈ $35.47 Million
0.064x +165.40%
2015-12-31 £403.65 Million
≈ $542.06 Million
£-39.23 Million
≈ $-52.68 Million
-0.097x -122.27%
2014-12-31 £152.29 Million
≈ $204.51 Million
£66.45 Million
≈ $89.23 Million
0.436x +1084.01%
2013-12-31 £220.16 Million
≈ $295.65 Million
£8.11 Million
≈ $10.90 Million
0.037x -80.04%
2012-12-31 £124.60 Million
≈ $167.33 Million
£23.00 Million
≈ $30.89 Million
0.185x +3.72%
2011-12-31 £63.43 Million
≈ $85.19 Million
£11.29 Million
≈ $15.16 Million
0.178x +33.42%
2010-12-31 £58.37 Million
≈ $78.38 Million
£7.79 Million
≈ $10.46 Million
0.133x +105.80%
2009-12-31 £59.80 Million
≈ $80.30 Million
£3.88 Million
≈ $5.21 Million
0.065x +122.39%
2008-12-31 £43.24 Million
≈ $58.06 Million
£-12.52 Million
≈ $-16.81 Million
-0.290x -303.62%
2007-12-31 £35.15 Million
≈ $47.20 Million
£-2.52 Million
≈ $-3.39 Million
-0.072x -106.31%
2006-12-31 £5.34 Million
≈ $7.18 Million
£6.08 Million
≈ $8.16 Million
1.137x -57.78%
2005-12-31 £631.00K
≈ $847.38K
£1.70 Million
≈ $2.28 Million
2.694x +1008.37%
2004-12-31 £-880.00K
≈ $-1.18 Million
£261.00K
≈ $350.50K
-0.297x --

About COSMO Pharmaceuticals SA

LSE:0RGI UK
Market Cap
$1.25 Billion
£927.14 Million GBP
Market Cap Rank
#7977 Global
#24 in UK
Share Price
£61.80
Change (1 day)
+0.98%
52-Week Range
£55.20 - £125.25
All Time High
£173.85
About

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesa… Read more